Brief: Acumen Pharmaceuticals Says Co On Track To Initiate Phase 2 Trial Evaluating Sabirnetug In First Half Of 2024
08/03/2024 14:42
March 8 (Reuters) - Acumen Pharmaceuticals Inc ABOS.O :
* ACUMEN PHARMACEUTICALS: ON TRACK TO INITIATE PHASE 2
TRIAL
EVALUATING SABIRNETUG IN FIRST HALF OF 2024 AND PHASE 1
SUBCUTANEOUS STUDY IN MID-2024
Source text for Eikon: ID:nGNX9TFj4z
Further company coverage: ABOS.O
((Reuters.Briefs@thomsonreuters.com;))